

Diagnostics of combined hereditary cardiovascular pathology in a teenager
https://doi.org/10.21508/1027-4065-2023-68-5-95-101
Abstract
Dilated cardiomyopathy is one of the leading causes of heart failure in children with a variety of clinical characteristics. A 12-year-old patient with dilated cardiomyopathy and heterozygous familial hypercholesterolemia, who underwent surgical treatment for implantation of the Abbott HeartMate III Left Ventricular Assist Device as a bridge to donor heart transplantation, is presented. Establishing an accurate diagnosis in the presented observation became possible thanks to the use of a modern molecular genetic method — whole genome DNA testing by next generation sequencing (NGS). The description of this case will help expand the range of possible clinical manifestations of dilated cardiomyopathy and reminds us of the importance of dynamic monitoring of children with cardiac arrhythmias.
Keywords
About the Authors
D. I. SadykovaRussian Federation
Kazan
O. S. Groznova
Russian Federation
Moscow
G. V. Pirogova
Russian Federation
Omsk
E. S. Slastnikova
Russian Federation
Kazan
L. F. Galimova
Russian Federation
Kazan;
Moscow
N. N. Firsova
Russian Federation
Kazan
A. A. Kucheriavaia
Russian Federation
Kazan
Ch. D. Khaliullina
Russian Federation
Kazan
References
1. Jefferies J.L., Towbin J.A. Dilated cardiomyopathy. Lancet 2010; 375: 752–762. DOI: 10.1016/S0140–6736(09)62023–7
2. Rossano J.W., Dipchand A.I., Edwards L.B., Goldfarb S., Kucheryavaya A.Y., Levvey B.J. et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth pediatric heart transplantation report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant 2016; 35: 1185–1195. DOI: 10.1016/j.healun.2016.08.018
3. Halliday B.P., Cleland J.G.F., Goldberger J.J., Prasad S.K. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation 2017; 136: 215–231. DOI: 10.1161/CIRCULATIONAHA.116.027134
4. Singh R.K., Canter C.E., Shi L., Colan S.D., Dodd D.A., Everitt M.D. et al. Survival without cardiac transplantation among children with dilated cardiomyopathy. J Am Coll Cardiol 2017; 70: 2663–2673. DOI: 10.1016/j.jacc.2017.09.1089
5. McNally E.M., Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res 2017; 121: 731–748. DOI: 10.1161/CIRCRESAHA.116.309396
6. Rusconi P., Wilkinson J.D., Sleeper L.A., Lu M., Cox G.F., Towbin J.A. et al. Differences in presentation and outcomes between children with familial dilated cardiomyopathy and children with idiopathic dilated cardiomyopathy. Circ: Heart Fail 2017e002637. DOI: 10.1161/CIRCHEARTFAILURE.115.002637
7. Dellefave L., McNally E.M. The genetics of dilated cardiomyopathy. Curr Opin Cardiol. 2010; 25: 198–204. DOI: 10.1097/HCO.0b013e328337ba52
8. García-Hernandez S., Iglesias L.M. Genetic Testing as a Guide for Treatment in Dilated Cardiomyopathies. Curr Cardiol Rep 2022; 24: 1537–1546. DOI: 10.1007/s11886–022–01772–8
9. Balder J.W., Lansberg P.J., Hof M.H., Wiegman A., Hutten B.A., Kuivenhoven J.A. Pediatric lipid reference values in the general population: The Dutch lifelines cohort study. J Clin Lipidol 2018; 12(5): 1208–1216. DOI: 10.1016/j.jacl.2018.05.011
10. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1736–1788. DOI: 10.1016/S0140–6736(18)32203–7
11. Harakalova M., Kummeling G., Sammani A., Linschoten M., Baas A.F., van der Smagt J. et al. A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. Eur J Heart Fail 2015; 17(5): 484–493. DOI: 10.1002/ejhf.255
12. Hershberger R.E., Givertz M.M., Ho C.Y., Judge D.P., Kantor P.F., McBride K.L. et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2018; 20: 899–909. DOI: 10.1038/s41436–018–0039-z
13. Bilinska Z.T., Michalak E., Piatosa B., Grzybowski J., Skwarek M., Deptuch T.W. et al. Familial dilated cardiomyopathy: evidence for clinical and immunogenetic heterogeneity. Med Sci Monit 2003; 9(5): CR167–74
14. Ezhov M.V., Bazhan S.S., Ershova A.I., Meshkov A.N., Sokolov A.A., Kukharchuk V.V. et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz 2019; 15(1): 58–98. (in Russ.)
15. Berberich A.J., Hegele R.A. A Modern Approach to Dyslipidemia. Endocr Rev 2022; 43(4): 611–653. DOI: 10.1210/endrev/bnab037
16. Sadykova D.I., Lutfullin I.Ja. Primary arterial hypertension and myocardial hypertrophy in childhood and adolescence. Pediatriya im. G.N. Speranskogo 2009; 88(5): 16–21. (in Russ.)
17. Di Salvo G., D’Aiello A.F., Castaldi B., Fadel B., Limongelli G., D’Andrea A. et al. Early left ventricular abnormalities in children with heterozygous familial hypercholesterolemia. J Am Soc Echocardiogr 2012; 25(10): 1075–1082. DOI: 10.1016/j.echo.2012.07.002
Review
For citations:
Sadykova D.I., Groznova O.S., Pirogova G.V., Slastnikova E.S., Galimova L.F., Firsova N.N., Kucheriavaia A.A., Khaliullina Ch.D. Diagnostics of combined hereditary cardiovascular pathology in a teenager. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2023;68(5):95-101. (In Russ.) https://doi.org/10.21508/1027-4065-2023-68-5-95-101